Myra Herrle News Today : Breaking News, Live Updates & Top Stories | Vimarsana

POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesUnited kingdomJoe mccannAlex loboMyra herrleTherapeutics acquisition corpResearch alliance corpRegulatory affairsBiopharma global incLeadership teamDevelopment expensesUs nuclear regulatory commissionCorporate affairsChief executive officerNorth americaTargeting technology

POINT Biopharma Strengthens Senior Management Team with

POINT Biopharma Strengthens Senior Management Team with
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesPeter kolchinskyJoe mccannWellcome glaxosmithklineMyra herrleMatthew hammondTherapeutics acquisition corpUniversity of oklahoma health sciences centerNational institute of environmental health sciencesResearch alliance corpRegulatory affairsCompany contactUniversity of puerto rico rio piedras campusBiopharma incVice present regulatory affairsOncology global regulatory affairs at abbvie

POINT Biopharma Strengthens Senior Management Team with Appointment of Dr Myra Rosario Herrle as EVP, Regulatory Affairs

POINT Biopharma Strengthens Senior Management Team with Appointment of Dr Myra Rosario Herrle as EVP, Regulatory Affairs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPeter kolchinskyJoe mccannAlex loboWellcome glaxosmithklineMyra herrleMatthew hammondTherapeutics acquisition corpUniversity of oklahoma health sciences centerNational institute of environmental health sciencesResearch alliance corpRegulatory affairsCompany contactUniversity of puerto rico rio piedras campusBiopharma incVice present regulatory affairs